Annual report pursuant to Section 13 and 15(d)

Shareholders Equity (Details Textual)

v3.20.1
Shareholders Equity (Details Textual)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Jan. 08, 2019
USD ($)
shares
Dec. 11, 2018
USD ($)
shares
Dec. 18, 2018
USD ($)
$ / shares
shares
Nov. 28, 2018
USD ($)
$ / shares
shares
Oct. 28, 2018
shares
Dec. 31, 2019
USD ($)
Employees
consultants
$ / shares
shares
Dec. 31, 2018
USD ($)
Employees
consultants
$ / shares
shares
Oct. 28, 2019
$ / shares
shares
Nov. 30, 2017
shares
May 31, 2017
$ / shares
shares
Shareholders Equity (Textual)                    
Common stock, par value | $ / shares           $ 0.0001        
Preferred stock, par value | $ / shares           $ 0.0001        
Fair value granted | $           $ 1,406 $ 1,451      
Weighted average exercise price | $ / shares           $ 0.01        
Share based compensation expenses | $           $ 732 405      
Unrecognized compensation expense | $           2,308 3,026      
Recongnized expense income | $           $ 241 $ 584      
Issuance of warrrants           236,552        
Warrants, description           a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product,b. 118,277 upon achievement of the earlier of the following milestone by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company’s licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement ) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product.        
Public warrants, description           ● in whole and not in part;● at a price of $0.01 per warrant;● at any time during the exercise period;● upon a minimum of 30 days’ prior written notice of redemption;● if, and only if, the last sale price of the Company’s common stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and● if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.        
Preferred Stock                    
Shareholders Equity (Textual)                    
Preferred stock, shares authorized           1,000,000        
New Incentive Plan [Member]                    
Shareholders Equity (Textual)                    
Grant options | $ / shares           $ 1,000        
Equity incentive plan, description           The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of Common Stock than provided herein.        
Stock Options [Member]                    
Shareholders Equity (Textual)                    
Purchase of ordinary shares           74,581 30,938      
Grant options | $ / shares           $ 527,716        
Grant approved           704,669 785,775      
Employees consideration | Employees           22 27      
Non-tradable options           79,630 199,481      
Consideration consultants | consultants           2 2      
Share based compensation, description             · 876,504 options were granted at an exercise prices of $1.97-$2.03 per share. 25% of the options vest and become exercisable on the first anniversary of the vesting commencement date. Thereafter, the options vest and become exercisable in 12 equal quarterly instalments of 6.25% each.· 108,752 options were granted at an exercise price of $1.69 per share and vest on variable vesting dates.      
Excercise price | $ / shares           $ 1.34 $ 0.001      
IPO [Member]                    
Shareholders Equity (Textual)                    
Offering price | $ / shares     $ 10.00              
Total gross proceeds | $     $ 70,000              
Consummated initial public offering     7,000,000              
Price Per Share | $ / shares     $ 11.50              
Retained transaction | $     $ 60,100              
Private Placement [Member]                    
Shareholders Equity (Textual)                    
Aggregate warrants shares     2,900,000              
Yeda [Member]                    
Shareholders Equity (Textual)                    
Shares of issued warrants                 7,615  
Founder [Member]                    
Shareholders Equity (Textual)                    
Shares of issued warrants                 2,974  
BiomX Isreal [Member]                    
Shareholders Equity (Textual)                    
Exchange for common shares         15,069,058          
Shares outstanding, percentage               65.00%    
Earnout shares, description           A. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share.B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share.C. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share.        
Purchase of ordinary shares           1        
License Agreement [Member]                    
Shareholders Equity (Textual)                    
Price Per Share | $ / shares                   $ 0.0001
Warrants to purchase Ordinary Shares                   591,382
Series A Preferred Stock [Member]                    
Shareholders Equity (Textual)                    
Preferred stock, shares issued             3,028,990      
Sale of stock, consideration | $             $ 13,000      
Series A Preferred Stock [Member] | Share Purchase Agreement [Member]                    
Shareholders Equity (Textual)                    
Preferred stock, shares issued       5,478,985            
Preferred stock, par value | $ / shares       $ 0.0001            
Sale of stock, consideration | $   $ 30,155   $ 31,955            
Shares issued   205,750                
Series A Preferred Stock [Member] | Share Purchase Agreement [Member] | Investors [Member]                    
Shareholders Equity (Textual)                    
Sale of stock, consideration | $ $ 1,800     $ 30,155            
Shares issued 308,628     4,964,607            
Common Stock [Member]                    
Shareholders Equity (Textual)                    
Common stock, shares issued           60,000,000        
Common stock, par value | $ / shares           $ 0.0001        
Common stock, shares outstanding           22,862,835        
Preferred Stock                    
Shareholders Equity (Textual)                    
Preferred stock, shares issued                  
Preferred stock, par value | $ / shares               $ 0.0001    
Preferred stock, shares authorized               1,000,000